The Indian market for GLP-1 drugs has not fully opened yet due to unavailability and affordability issues. However, Indian drugmakers are gearing up to launch copycat weight-loss drugs as the patents for Novo Nordisk’s brands are set to expire. Experts anticipate a rise in demand for these drugs in India, considering the country’s high rates of obesity and diabetes. While the price of these drugs is currently high, it’s uncertain whether the cost will significantly decrease once generics are introduced. Overall, the industry is expected to see a shift with new and more affordable options becoming available in the coming years. Indian pharmaceutical companies are gearing up to enter the market with their generic versions of Novo Nordisk’s GLP-1 drugs, Ozempic and Wegovy, as the patents are set to expire. Major players like Sun Pharma, Biocon, Dr Reddy’s, and others are working on developing these generic drugs. The competition is expected to intensify once the patents expire, leading to a potential price war. The Indian government is also supporting the production of GLP-1 drugs under the PLI scheme. Patients may benefit from increased competition, but the company offering the lowest cost and meeting market demands on a large scale will likely emerge as the winner.
source
Discover more from GLOBALMALAYALAM.NEWS
Subscribe to get the latest posts sent to your email.
